The Only FDA-Approved Prescription Hydrogel and Lidocaine HCl 4% for Pain Associated with Wound Healing and Vasculitis
The only FDA-approved prescription containing 4% Lidocaine HCl in a hydrogel that provides the relief of pain associated with Closed Skin, Non-Penetrating and Open Wounds, as well as a treatment for wound healing and vasculitis. more…
Lidocaine HCl Transdermal Gel for Rapid Anesthesia and Site-Specific Relief of Pain.
LiDORx® provides topical non-narcotic temporary relief for pain as prescribed by a physician. more…
Prepare for the Flare with the First Transdermal Treatment for Gout Flares
ColciGel® is the first prescription transdermal gel indicated for treatment and prophylaxis of gout flares in adults. more…
NEWLY LAUNCHED
The Single Dose™ Topical Anesthetic & Antiseptic for Preprocedural Use.
LidoDose®, is a topical anesthetic in a single-use foam applicator. For preparation of the skin prior to an injection. For pain associated with any procedure requiring penetration of the skin, such as dialysis, vaccinations, venipuncture and other procedures. more…
A Non-NSAID Alternative for Pain, Inflammation, and Bruising
SpeedGel Rx® is a prescription transdermal analgesic gel that provides relief of pain and inflammation utilizing a patented Isopeutic® Transdermal Technology. more…
Copay/Cash Pay Program
Need help with prescription costs?
Save with the Gensco Pharma Savings Cards
Learn more about the Gensco Pharma®
Co-pay/Cash Pay Programs
LOOKING TO THE FUTURE
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology.
GENSCO® TRENDING
Looking To The Future
RizaFilm migraine treatment launching Q5
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology—offering unmatched convenience, portability, and speed in a tablet-dominated market.
- Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort® May 13, 2025 Featured, Industry, Press Release, Product Update - Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch… more...
- Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States September 26, 2023 Featured, Industry, Press Release, Product Update - Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch… more...
- Skin Tears Treatment Market to Observe Strong Development by 2018-2026 April 15, 2019 Articles, Featured, Industry - [To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019… more...
- Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in… more...